Answer Questions About Myinfla for CV Risk Reduction

You'll hear about Myinfla (extended-release colchicine) to reduce the risk of CV events in patients with coronary artery disease (CAD).

We're used to seeing immediate-release colchicine 0.6 mg for gout...or off-label for pericarditis.

But there's growing interest in using colchicine's anti-inflammatory effects for other cardiac indications...since inflammation is thought to be a CV risk factor.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote